Gabriel Weigel

Mr. Gabriel Weigel

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2024 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
ADAshley A Darakjian
Ashley A Darakjian
MBMira Bhutani
Mira Bhutani
DFDeLisa Fairweather
DeLisa Fairweather
SKS Christian Kocsis
S Christian Kocsis
JFJessica J Fliess
Jessica J Fliess
KBKatelyn Ann Bruno
Katelyn Ann Bruno
Objectives: Patients with hypermobile Ehlers–Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) experience a wide array of symptoms and system disorders. This study aimed to identify whether differences occurred in 115 self-reported symptoms and comorbidities in patients diagnosed with hEDS or HSD. Methods: In this study we analysed self-reported data from an EDS Clinic intake questionnaire in patients diagnosed with hEDS, HSD or no hypermobile conditions. Results: From 1 November 2019 to 7 March 2024, the EDS Clinic saw 2088 patients. Using the 2017 diagnostic criteria, 66.5% were diagnosed with HSD (n = 1389), 20.3% with hEDS (n = 423), 10.6% with historic HSD (H-HSD) or localized HSD (L-HSD) (n = 256) (hypermobile controls) and 2.6% were not diagnosed with hEDS, HSD, H-HSD or L-HSD (n = 55) (controls). Symptoms/comorbidities that occurred with high prevalence in both hEDS and HSD included joint pain (hEDS 82.0%, HSD 88.9%), allergy (hEDS 77.0%, HSD 77.0%), subluxations (hEDS 71.2%, HSD 72.6%), brain fog (hEDS 70.0%, HSD 74.7%), headache (hEDS 68.1%, HSD 69.1%), anxiety (hEDS 60.3%, HSD 69.3%), depression (hEDS 52.2%, HSD 58.0%), migraine (hEDS 53.7%, HSD 52.5%), nausea (hEDS 54.6%, HSD 59.5%) and constipation (hEDS 53.0%, HSD 57.2%). In contrast, 9/115 (8%) symptoms/comorbidities were self-reported significantly more often in hEDS but 42/115 (37%) in HSD. hEDS patients reported more symptoms that suggest a defect in collagen, such as dislocation, hernias and rectal prolapse, while HSD patients reported more joint, muscle, allergy, neurological, gastrointestinal, sleep and psychological symptoms/comorbidities. Conclusion: Although we found an overlap in some symptoms and comorbidities self-reported by hEDS/HSD patients, such as allergy/atopy, headache/migraine and gastrointestinal symptoms, our findings suggest key differences exist between the two diagnoses, suggesting that hEDS and HSD may be distinct conditions.

26 November 2025 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
DBDanielle J. Beetler
Danielle J. Beetler
PGPresley Giresi
Presley Giresi
VXVivian Xu
Vivian Xu
EMElizabeth J. McCabe
Elizabeth J. McCabe
JFJessica J. Fliess
Jessica J. Fliess
DFDeLisa Fairweather
DeLisa Fairweather
Extracellular vesicles (EVs) are promising therapeutics for diseases associated with inflammation and tissue remodeling. However, a major limitation for th

29 July 2026 in Cells
Verified
Journal Article
Open access
PDF file
KKKhashim Khashim
Khashim Khashim
SSSwikriti Shrestha
Swikriti Shrestha
SHShaimaa Hassoun
Shaimaa Hassoun
ELEthan William Law
Ethan William Law
ASAnna Marie Schornack
Anna Marie Schornack
QPQuinn P Peterson
Quinn P Peterson
Stem cell-derived β (SC-β) cells are a promising therapy for type 1 diabetes (T1D), but their long-term efficacy is limited by immune-mediated graft rejection. Platelet-derived exosome product (PEP) has emerged as a novel immunomodulatory agent, although its effect on SC-β cell xenograft rejection remains unclear. Here, we evaluated PEP in stimulated human peripheral blood mononuclear cells (PBMCs) and in an immunocompetent mouse model of SC-β cell transplantation under the kidney capsule. Immune-related gene expression was assessed by quantitative PCR, immune cell infiltration by immunofluorescence, and graft function by circulating human insulin. In vitro, PEP reduced NK-cell-associated gene expression, including NK1.1, EOMES, and KLRK1, and increased IL-10 expression. In vivo, untreated SC-β cell xenografts showed progressive immune infiltration and loss of detectable human insulin by day 14, whereas PEP-treated grafts retained detectable insulin through day 14 across co-transplantation, pretreatment, and systemic administration strategies. PEP co-transplantation delayed, but did not prevent, xenograft rejection, with graft loss observed by day 21. This delay was associated with reduced NK1.1+ cell infiltration and lower expression of selected inflammatory and rejection-associated markers, including NK1.1, Nos2, and Nlrp3. These findings suggest that PEP modulates graft-associated immune responses and may serve as an adjunct immunomodulatory strategy for stem cell-based therapies for type 1 diabetes. Further studies are needed to evaluate sustained graft durability, safety, and translational efficacy.

8 October 2026 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
EWEmily R. Whelan
Emily R. Whelan
EPEvan E. Perona
Evan E. Perona
JFJessica J. Fliess
Jessica J. Fliess
SKS. Christian Kocsis
S. Christian Kocsis
GWGabriel Weigel
Gabriel Weigel
DFDeLisa Fairweather
DeLisa Fairweather
Background: Radiation-induced heart disease (RIHD) may develop months to years following radiation therapy for cancers near the heart such as lung or breast cancer. Several mouse models of RIHD exist to study the pathogenesis of disease, but to our knowledge no studies have examined whether sex differences exist in RIHD in mice. Methods: Female and male BALB/cJ mice received a single whole-heart dose of 22 Gy (Gy) radiation via a C5 collimator vs. sham controls that received 0 Gy, anesthesia and were placed in the X-ray machine for the same length of time. Endpoints were examined at 24 h (innate), day 10 (acute) and day 35 (chronic) post irradiation. Results: Females and males developed dsDNA breaks from radiation at day 10 but females had more damage than males ( p < 0.001). Vessel area and wall thickness were increased by radiation at day 10 and 35 but vessel area was greater in irradiated males than females at day 35 ( p = 0.003). Bulk RNA sequencing of the heart at day 10 revealed that females and males developed similar gene pathway responses to radiation by upregulating cellular repair pathways and developing mitochondrial dysfunction. However, females upregulated the master regulator of mitochondrial function, Pgc1α ( p = 0.0001), suggesting possible improved mitochondrial repair in females. By day 35, females developed mild cardiomyopathy while males developed myocardial and perivascular fibrosis and inflammatory dilated cardiomyopathy (iDCM). Conclusions: We observed sex differences in most cardiac parameters that we examined following radiation exposure. BALB/c males exposed to 22 Gy radiation developed iDCM by day 35 while females developed mild cardiomyopathy. Further research is needed to better understand mechanisms driving sex differences in RIHD using translational animal models.